We are live on ! Find out more
MLTX icon

MoonLake Immunotherapeutics
MLTX

23 hedge funds and large institutions have $190M invested in MoonLake Immunotherapeutics in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

54% more capital invested

Capital invested by funds: $123M → $190M (+$66.7M)

1.8% more ownership

Funds ownership: 96.95% → 98.75% (+1.8%)

15% less funds holding

Funds holding: 27 → 23 (-4)

21% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 19

Holders
23
Holders Change
-4
Holders Change %
-14.81%
% of All Funds
0.39%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
15
Increased
5
Reduced
2
Closed
19
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$137M
2
CAM
Cormorant Asset Management
Massachusetts
+$17.5M
3
Citadel Advisors
Citadel Advisors
Florida
+$12.6M
4
TCM
TCG Crossover Management
California
+$6.29M
5
RI
RTW Investments
New York
+$3.14M

Top Sellers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
-$7.9M
2
Marshall Wace
Marshall Wace
United Kingdom
-$7.26M
3
SCA
STALEY CAPITAL ADVISERS
Pennsylvania
-$6.35M
4
BCM
Beryl Capital Management
California
-$5.1M
5
AWG
Alpha Wave Global
New York
-$4.49M
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$114M +$137M +21,751,284 New
CAM
2
Cormorant Asset Management
Massachusetts
$30.9M +$17.5M +2,785,001 +85%
Citadel Advisors
3
Citadel Advisors
Florida
$13.9M +$12.6M +2,003,765 +287%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$6.26M +$1.82K +290 +0%
TCM
5
TCG Crossover Management
California
$5.25M +$6.29M +1,000,000 New
T. Rowe Price Associates
6
T. Rowe Price Associates
Maryland
$4.44M +$1.91M +304,333 +54%
BlackRock
7
BlackRock
New York
$3.9M – – –
RI
8
RTW Investments
New York
$2.63M +$3.14M +500,000 New
GPP
9
Great Point Partners
Connecticut
$2.27M +$2.72M +432,000 New
TCM
10
Tang Capital Management
California
$1.68M +$2.01M +319,043 New
GTC
11
Ghost Tree Capital
New York
$1.57M +$1.89M +300,000 New
MIM
12
Monashee Investment Management
Massachusetts
$1.05M +$1.26M +200,000 New
Citigroup
13
Citigroup
New York
$835K +$1,000K +159,087 New
UBS Group
14
UBS Group
Switzerland
$387K +$452K +71,968 +4,253%
AA
15
ALPS Advisors
Colorado
$164K +$196K +31,260 New
TD Asset Management
16
TD Asset Management
Ontario, Canada
$152K +$182K +28,966 New
Millennium Management
17
Millennium Management
New York
$147K -$755K -120,135 -81%
MWM
18
Meridian Wealth Management
Kentucky
$142K -$94.9K -15,094 -36%
CAC
19
Cowen and Company
New York
$85K +$102K +16,173 New
Barclays
20
Barclays
United Kingdom
$79K +$94.8K +15,083 New
Goldman Sachs
21
Goldman Sachs
New York
$62K +$74.1K +11,785 New
PCM
22
Penserra Capital Management
California
$16K +$20.1K +3,195 New
6CM
23
683 Capital Management
New York
– -$7.9M -790,000 Closed
Marshall Wace
24
Marshall Wace
United Kingdom
– -$7.26M -653,872 Closed
SCA
25
STALEY CAPITAL ADVISERS
Pennsylvania
– -$6.35M -580,000 Closed
1
2

MLTX Hedge Fund Activity: Q2 2022 in Review

23 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q2 2022, worth a combined $190M — up 54% from $123M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of MLTX and 15 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 5 added.

The largest buyer was BVF Inc, opening a new position worth an estimated $137M. The largest seller was 683 Capital Management, exiting entirely with an estimated $7.9M sold.

  • 23 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q2 2022, down from 27 in Q1 2022.
  • Funds reported $190M of MoonLake Immunotherapeutics stock for Q2 2022, up 54% quarter-over-quarter.
  • 15 funds opened new MoonLake Immunotherapeutics positions in Q2 2022 and 19 closed out, a net change of -4 holders.
  • The largest MoonLake Immunotherapeutics buyer in Q2 2022 was BVF Inc, an estimated $137M added.
  • The largest MoonLake Immunotherapeutics seller in Q2 2022 was 683 Capital Management, an estimated $7.9M sold.

Based on aggregated 13F filings for Q2 2022.